The £40 million BioHub is the iconic new location for life sciences in Aberdeen.
This year will be a landmark for life sciences in north east Scotland with the launch of the unique and transformational BioHub in spring. Creating a focal point for commercialisation and entrepreneur...
Dr Deborah O'Neil OBE explains why entrepreneurial growth is at the heart of north east Scotland's vision for life sciences.
We are looking for a social media expert to join our Life Sciences team in Aberdeen. Our Digital Marketing and Community Building Executive is a new and exciting role.
Dr Ruta Dekeryte and Dr Andrew McEwan are two innovators working on novel treatments for type two diabetes, obesity and cardiovascular disease.
BioHub is a £40 million investment to double the size of north east Scotland’s high-value life sciences sector.
Life sciences innovation, investment, impact was the focus for a major summit in Aberdeen supported by ONE and BioHub, attracting sector leaders from across the UK.
New investment in £40 million BioHub project to make Aberdeen city region a centre for life sciences research commercialisation and growth.
Join life sciences leaders from across the UK in Aberdeen on 30 March to explore innovation, investment and impact at the 2022 Life Sciences Summit.
The transformational BioHub project for Aberdeen's life sciences sector provides an economic boost for the construction sector and creates career pathways for young people in the city.
Turn your tech, food and drink, or life sciences idea into a business with Opportunity North East’s dedicated sector start-up programmes, starting in January 2022.
The Aberdeen City Region Deal is playing a key role in supporting economic recovery and the creation of green jobs for the future across Aberdeen City and Aberdeenshire.
An Aberdeen life scientist at high-growth biotech company, Elasmogen has secured a prestigious national leadership fellowship from UK Research and Innovation (UKRI).
Researchers in Aberdeen with a novel treatment for diabetes and a mobile scanner for head injuries are part of the new cohort of life sciences founders supported by Opportunity North East.
Scottish and UK Governments hail progress on transformational £40 million Aberdeen BioHub project.
The North East of Scotland is placing itself firmly at the forefront of digital and technology developments.
Plans to make Aberdeen one of the most dynamic locations in the UK for life sciences company creation and growth drive ahead with BioHub entering its main construction phase.
ONE is supporting the next wave of entrepreneurs in the high-growth life sciences sector in Aberdeen.
Opportunity North East (ONE) is launching its third dedicated accelerator programme as part of action and investment to double the size of the region’s high-growth life sciences company cluster.
As 2020 draws to a close, ONE Life Sciences chair Prof Stephen Logan shares his thoughts on the year and looks ahead to 2021.
Two innovative early-stage life sciences business concepts are being developed in Aberdeen with support from an Opportunity North East (ONE) sector start-up programme.
A key figure in the drive to double the size of the life sciences sector in Aberdeen has joined the national industry leadership group.
The action and investment in life sciences in north east Scotland and the national sector strategy and recovery plans are closely aligned.
A plan setting out the life sciences industry priorities in response to Covid-19 and to support continuing growth across the key economic sector has been published.
The successful commercialisation journey of Aberdeen medtech business Sirakoss will be the focus for the next ONE Life Sciences Network meeting on 9 December.
The transformational £40 million BioHub project to double the size of north east Scotland’s high-growth life sciences company cluster will move into its main construction phase in the new year.
NovaBiotics, the Aberdeen-based clinical-stage antimicrobials drug discovery company, has secured £1 million in funding from Innovate UK to prepare for clinical studies of a potentially game-changing ...
Aberdeen medtech company Sirakoss has been acquired by Swedish firm OssDsign for an initial cash consideration of $11 million plus milestone and royalty payments.
Aberdeen Science Centre has a transformational new look after a £6 million refurbishment, supported and part-funded by Opportunity North East (ONE).
A new programme from Opportunity North East will help life sciences businesses in north east Scotland to prepare for raising investment.
Opportunity North East (ONE) is helping the region’s next generation of life sciences entrepreneurs to turn research and ideas into new businesses.
The virtual ONE Life Sciences Network meeting, on 23 September, will explore the regional response to COVID-19 with a focus on sector strengths in biologics and health data science.
Academics, clinicians and industry are collaborating in Aberdeen to apply artificial intelligence to fracture diagnosis in hospitals.
Professor Stephen Logan, chair of the ONE Life Sciences sector board, reflects on the economic value of the sector in north east Scotland its role in economic recovery.
A new Opportunity North East (ONE) programme aims to turn research and ideas into growing life sciences businesses.
The fifth ONE Life Sciences Leadership Forum will explore how data visualisation can support industry innovation and achieve faster and informed decision making.
The Aberdeen City Region Deal (ACRD) Joint Committee today (Friday 24 July) underlined its commitment to the Bio-therapeutics Hub for Innovation (BioHub) project.
US Food and Drug Administration clearance will enable Sirakoss to pursue commercialisation of its game-changing bone graft substitute.
Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new UKRI grants worth £374,000 to support programmes for COVID-19 and oncology.
Digital profile and online engagement are more important than ever in today's life sciences market, whether you are targeting funding or investors, partners or customers.
Professor Stephen Logan, chair of the Opportunity North East (ONE) life sciences sector board, sets out the prospects for the sector as it addresses the COVID-19 pandemic.
North east Scotland’s life sciences sector is applying its expertise to COVID-19 with companies, researchers, academics and clinicians collaborating and innovating to tackle the pandemic.
The University of Aberdeen and Vertebrate Antibodies Ltd will use artificial intelligence technology to develop a mass screening test for COVID-19.
Pregnancy style tests for COVID-19 are being developed by the University of Aberdeen and biologics company Elasmogen.
NovaBiotics is repurposing its experimental drug Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections.
Six University of Aberdeen research projects have been awarded almost £1 million by the Scottish Government as part of the country’s response to the COVID-19 pandemic.
Britain’s small businesses will be able to apply for quick and easy-to access loans of up to £50,000 from today – with the cash expected to land within days.
A new £100 million Scottish Government fund for businesses impacted by COVID-19 is now accepting applications.
Planning permission granted for the BioHub a transformational project for the life sciences sector in north east Scotland.
Writing in The Sunday Times on 8 March 2020, Prof Stephen Logan, chair of the ONE Life Sciences sector board, set out the industry’s growth ambition in north east Scotland.
The success of an Aberdeen geneticist in translating research into industry inspired a Nobel prize-winning scientist who developed the world’s biggest-selling drug.
Major changes in how we research, diagnose, and treat disease and illness are creating new challenges and opportunities that north east Scotland’s life sciences sector can lead in tackling
A new £2m private sector fund is being rolled out to support business growth and employment across North East Scotland’s key industry sectors.
Opportunity North East (ONE) and the Scottish Government have announced the five organisations selected for the first stage of a landmark project to develop artificial intelligence (AI) solutions to s...
Leading technology and life sciences entrepreneur, Dr Jamie Coleman will be the guest speaker at Opportunity North East’s (ONE) next Life Sciences network meeting on the 3rd September at the ONE Tech ...
X-rays of arms and legs are among the most frequent diagnosis processes used by NHS Scotland, with around 5,000 procedures annually.
Two senior figures from the life sciences industry will share their perspectives and insights on leadership at the next ONE Life Sciences network meeting in Aberdeen on 16 May 2019.
BDP has been appointed as multi-discipline design team consultant for the Bio-therapeutics Hub for Innovation in Aberdeen, Scotland.
Your privacy matters to us so if you want to find out more on how we keep your data safe, view our Privacy Notice or talk to ONE direct.
Opportunity North East Ltd
11 Queens Gardens